Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
321GO feasibility study of reduced-intensity chemotherapy in frail or elderly advanced gastroesophageal cancer
ISRCTN33934807Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Sep 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of epirubicin, oxaliplatin and capecitabine in gastric adenocarcinoma, esophageal cancer and esophagogastric junction cancer (3 arms), sponsored by University of Leeds. Primary endpoints: Randomization rate and Proportion of eligible palliative patients randomized. Started Sep 2008; status: completed.
02
Drugs
epirubicinoxaliplatincapecitabine
03
Conditions
gastric adenocarcinomaesophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ISRCTN33934807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33934807.